January 11th 2025
Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
How to Avoid the Number One Reason for Receiving FDA 483s
March 15th 2017An enterprise quality management software system can minimize human error and help pharmaceutical manufacturers maintain standard operating procedures to prevent deviations from GMP resulting from not having or following written procedures.